Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025 16:03 ET
|
Kura Oncology, Inc.
– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR...
Kura Oncology to Participate in Three Upcoming Investor Conferences
February 25, 2025 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
February 19, 2025 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
February 05, 2025 16:01 ET
|
Kura Oncology, Inc.
– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting – – NDA submission for ziftomenib on track...
Kura Oncology Announces Senior Executive Promotions
January 06, 2025 16:30 ET
|
Kura Oncology, Inc.
– Mollie Leoni, M.D. promoted to Chief Medical Officer – – Francis Burrows, Ph.D. promoted to Chief Scientific Officer – – Stephen Dale, M.D., steps down as CMO and Head of R&D to prioritize...
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
December 09, 2024 07:00 ET
|
Kura Oncology, Inc.
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients...
Kura Oncology to Host Virtual Investor Event on December 9, 2024
December 02, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
November 25, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...